Evolve BioSystems announced it completed a substantial first close in a $55 million Series D round of funding, led by Cargill and Manna Tree.

Evolve BioSystems manufactures Evivo, a proprietary probiotic proven to resolve infant gut dysbiosis, or Newborn Gut Deficiency. Evivo is comprised of activated B. infantis EVC001, which studies have shown guides critical development of infants' digestive and immune systems. Evivo restores this missing bacterium to the infant gut microbiome, reducing potentially pathogenic bacteria by 80 percent as well as significantly reducing intestinal inflammation.